Coamplification of Myc/Pvt1 and homozygous deletion of Nlrp1 locus are frequent genetics changes in mouse osteosarcoma

Osteosarcomas (OSs) are characterized by high levels of genomic instability (GI). To gain insights into the GI and its contribution toward understanding the genetic basis of OS, we characterized 19 primary and 13 metastatic mouse tumors in a genetically engineered novel mouse model of OS by a combination of genomic techniques. Through the bone‐specific deletion of the wild‐type Trp53 locus or activation of a metastatic‐promoting missense R172Hp53 allele, C57BL/6 mice developed either localized or metastatic OS. Subsequent tumors were isolated and primary cultures created from primary bone and/or distal metastatic lesions, for example, lung and liver. These tumors exhibited high levels of GI with complex chromosomal rearrangements, amplifications, and deletions comparable to human OS. The combined genomic approaches identified frequent amplification of chromosome 15D1 and loss of 11B4 by CGH and/or SKY. Both 15D1 and 11B4 have homology with frequently altered chromosomal bands 8q24 and 17p13 in human OS, respectively. Subsequent array CGH, FISH, and qRT‐PCR analysis identified coamplification and overexpression of Myc/Pvt1 transcripts from the 15D1 amplicon and loss and decreased expression of the Nlrp1b from 11B4. The Nlrp1 gene is the key mediator of apoptosis and interacts strongly with caspase 2. © 2015 Wiley Periodicals, Inc.

[1]  L. Donehower,et al.  NKD2, a negative regulator of Wnt signaling, suppresses tumor growth and metastasis in osteosarcoma , 2015, Oncogene.

[2]  D. Largaespada,et al.  PVT1 dependence in cancer with MYC copy-number increase , 2014, Nature.

[3]  Christopher W. Whelan,et al.  Genomic organization and evolution of double minutes/homogeneously staining regions with MYC amplification in human cancer , 2014, Nucleic acids research.

[4]  Li Ding,et al.  Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. , 2014, Cell reports.

[5]  N. Caplen,et al.  p53-dependent Induction of PVT1 and miR-1204* , 2011, The Journal of Biological Chemistry.

[6]  Michael A Choti,et al.  Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma , 2011, Nature Genetics.

[7]  L. You,et al.  Genome-wide screen identifies PVT1 as a regulator of Gemcitabine sensitivity in human pancreatic cancer cells. , 2011, Biochemical and biophysical research communications.

[8]  K. Janeway,et al.  Modeling human osteosarcoma in the mouse: From bedside to bench. , 2010, Bone.

[9]  A. Ashworth,et al.  A genome-wide association study of Hodgkin Lymphoma identifies new susceptibility loci at 2p16.1 (REL), 8q24.21, and 10p14 (GATA3) , 2010, Nature Genetics.

[10]  Daniel Birnbaum,et al.  Genome profiling of ERBB2-amplified breast cancers , 2010, BMC Cancer.

[11]  Hanlee P. Ji,et al.  Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas. , 2010, Cancer research.

[12]  Lawrence A. Donehower,et al.  20 years studying p53 functions in genetically engineered mice , 2009, Nature Reviews Cancer.

[13]  L. Donehower,et al.  MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression. , 2009, Cancer research.

[14]  Lawrence S. Hon,et al.  High-resolution analysis of copy number alterations and associated expression changes in ovarian tumors , 2009, BMC Medical Genomics.

[15]  F. Alt,et al.  Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. , 2008, Genes & development.

[16]  R. Bajaj,et al.  Double-minute MYC amplification and deletion of MTAP, CDKN2A, CDKN2B, and ELAVL2 in an acute myeloid leukemia characterized by oligonucleotide-array comparative genomic hybridization. , 2008, Cancer genetics and cytogenetics.

[17]  M. Ladanyi,et al.  Cell Cycle Regulator Gene CDC5L, a Potential Target for 6p12-p21 Amplicon in Osteosarcoma , 2008, Molecular Cancer Research.

[18]  R. Stephens,et al.  The Identification of MicroRNAs in a Genomically Unstable Region of Human Chromosome 8q24 , 2008, Molecular Cancer Research.

[19]  N. Caplen,et al.  Pvt1-encoded microRNAs in oncogenesis , 2008, Retrovirology.

[20]  Wen-Lin Kuo,et al.  Amplification of PVT1 Contributes to the Pathophysiology of Ovarian and Breast Cancer , 2007, Clinical Cancer Research.

[21]  A. Osterman,et al.  Bcl-2 and Bcl-XL Regulate Proinflammatory Caspase-1 Activation by Interaction with NALP1 , 2007, Cell.

[22]  Shishir Shah,et al.  Genome-wide array comparative genomic hybridization analysis reveals distinct amplifications in osteosarcoma , 2004, BMC Cancer.

[23]  A. Huvos,et al.  Frequent amplification and rearrangement of chromosomal bands 6p12‐p21 and 17p11.2 in osteosarcoma , 2004, Genes, chromosomes & cancer.

[24]  Michael B. Elowitz,et al.  The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[25]  J. Wunder,et al.  Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma , 2001, Cancer.

[26]  M. Kapoor,et al.  High metastatic potential in mice inheriting a targeted p53 missense mutation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[27]  M. Schwab Oncogene amplification in solid tumors. , 1999, Seminars in cancer biology.

[28]  K. Kinzler,et al.  Genetic instabilities in human cancers , 1998, Nature.

[29]  R. Romagnoli,et al.  Malignant tumors of the osteogenic matrix. , 1998, European Journal of Radiology.

[30]  P. Kleihues,et al.  Tumors associated with p53 germline mutations: a synopsis of 91 families. , 1997, The American journal of pathology.

[31]  A. Zetterberg,et al.  Detection of TP53 gene mutations in human sarcomas. , 1995, European journal of cancer.

[32]  L. Donehower,et al.  Spontaneous and carcinogen–induced tumorigenesis in p53–deficient mice , 1993, Nature Genetics.

[33]  D. Pinkel,et al.  Comparative Genomic Hybridization for Molecular Cytogenetic Analysis of Solid Tumors , 2022 .

[34]  M. Fernö,et al.  c‐myc amplification is an independent prognostic factor in postmenopausal breast cancer , 1992, International journal of cancer.

[35]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[36]  A. Palumbo,et al.  Human homologue of Moloney leukemia virus integration-4 locus (MLVI-4), located 20 kilobases 3' of the myc gene, is rearranged in multiple myelomas. , 1990, Cancer research.

[37]  D. V. Von Hoff,et al.  Double minutes arise from circular extrachromosomal DNA intermediates which integrate into chromosomal sites in human HL-60 leukemia cells. , 1990, The Journal of clinical investigation.

[38]  B. Spengler,et al.  Homogeneously Staining Regions and Double Minute Chromosomes, Prevalent Cytogenetic Abnormalities of Human Neuroblastoma Cells , 1983 .